<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="170">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006164</url>
  </required_header>
  <id_info>
    <org_study_id>HALT C</org_study_id>
    <secondary_id>N01-DK-9-2328</secondary_id>
    <secondary_id>N01-DK-9-2323</secondary_id>
    <secondary_id>N01-DK-9-2324</secondary_id>
    <secondary_id>N01-DK-9-2325</secondary_id>
    <secondary_id>N01-DK-9-2326</secondary_id>
    <secondary_id>N01-DK-9-2321</secondary_id>
    <secondary_id>N01-DK-9-2327</secondary_id>
    <secondary_id>N01-DK-9-2319</secondary_id>
    <secondary_id>N01-DK-9-2318</secondary_id>
    <secondary_id>N01-DK-9-2320</secondary_id>
    <secondary_id>N01-DK-9-2322</secondary_id>
    <nct_id>NCT00006164</nct_id>
    <nct_alias>NCT00006139</nct_alias>
  </id_info>
  <brief_title>Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment</brief_title>
  <acronym>HALT-C</acronym>
  <official_title>Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial (HALT-C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Minority Health and Health Disparities (NIMHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases
      sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated
      interferon) in patients who failed to respond to prior interferon treatment. All patients
      who enter the trial will be treated for 6 months with Peginterferon alfa-2a and Ribavirin.
      Patients who respond to this 6 month treatment will continue to be treated for an additional
      6 months.

      Patients who do not respond to this treatment will be eligible for the long-term maintenance
      phase of this study where patients will be randomly selected to be treated with
      Peginterferon alfa-2a or to discontinue treatment for 3.5 years. Patients in both arms of
      this study will be followed closely with quarterly study visits.

      The combination of peginterferon plus ribavirin has recently been approved by the FDA for
      treatment of chronic HCV. Patients who remain HCV-RNA positive after being treated for at
      least 6 months with peginterferon and ribavirin outside of this study may be eligible to
      directly enter the randomized portion of the HALT-C Trial.

      The HALT-C study is designed to determine if continuing interferon long-term over several
      years will suppress Hepatitis C virus, prevent progression to cirrhosis, prevent liver
      cancer and reduce the need for liver transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2000</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Increase in Ishak Fibrosis Score by 2 Points or More at 2 or 4 Year Biopsies</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Death From Any Cause</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of Hepatocellular Carcinoma (HCC)</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Variceal Hemorrhage</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Ascites</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Spontaneous Bacterial Peritonitis</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Hepatic Encephalopathy</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Events Requiring Dose Reductions (in Both Treatment Groups).</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Fibrosis From Baseline at Year 2 or Year 4 Biopsy.</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presumed Hepatocellular Carcinoma (HCC)</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1400 days (3.85 years) post randomization</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1050</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Cirrhosis, Liver</condition>
  <condition>Fibrosis, Liver</condition>
  <condition>Hepatic Cirrhosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peg-interferon alfa-2a 90 mcg/week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard of care followup</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a + Ribavirin</intervention_name>
    <description>Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight &lt;75 kg, &gt;75 kg) daily in two divided doses for 24 weeks</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Pegasys (Hoffman-La Roche)</other_name>
    <other_name>Copegus (Hoffman-La Roche)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peginterferon alfa-2a</intervention_name>
    <description>90 mcg/week injection, for 3.5 years</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Pegasys (Hoffman-La Roche)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age at entry at least 18 years.

          -  Positive for Hepatitis C.

          -  Previous treatment with any interferon or interferon and ribavirin for at least 3
             months.

          -  Documented non-response to treatment with interferon.

          -  A liver biopsy demonstrating significant liver scarring.

        Exclusion Criteria:

          -  No other liver disease.

          -  No unstable major medical diseases or conditions.

          -  No major complications of cirrhosis.

          -  No recent abuse of alcohol or illicit drugs.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory T. Everson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCHSC (University of Colorado)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adrian M. Di Bisceglie, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William M. Lee, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas, Southwestern Medical Center at Dallas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marc Ghany, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>LDS, NIDDK, NIH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jules L. Dienstag, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mitchell Shiffman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Virginia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Lok, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tim Morgan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California-Irvine/VA Medical Center-Long Beach</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karen Lindsay, M.D., M.M.M.</last_name>
    <role>Principal Investigator</role>
    <affiliation>USC School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gyongyi Szabo, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMass Medical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California-Irvine/VA Medical Center-Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCHSC (University of Colorado)</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Connecticut Health Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lds, Niddk, Nih</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1800</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMass Memorial HealthCare, University Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.haltctrial.org</url>
    <description>HALT-C Web Site</description>
  </link>
  <reference>
    <citation>Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE; HALT-C Trial Group. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004 Oct;25(5):472-92.</citation>
    <PMID>15465617</PMID>
  </reference>
  <results_reference>
    <citation>Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL; HALT-C Trial Investigators. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008 Dec 4;359(23):2429-41. doi: 10.1056/NEJMoa0707615.</citation>
    <PMID>19052125</PMID>
  </results_reference>
  <verification_date>January 2010</verification_date>
  <lastchanged_date>January 12, 2010</lastchanged_date>
  <firstreceived_date>August 8, 2000</firstreceived_date>
  <firstreceived_results_date>June 9, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>James E. Everhart, MD, MPH, Project Officer</name_title>
    <organization>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</organization>
  </responsible_party>
  <keyword>liver disease</keyword>
  <keyword>hepatitis c virus</keyword>
  <keyword>antiviral agent</keyword>
  <keyword>cirrhosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
  </intervention_browse>
  <!-- Results are available for this study                                           -->
</clinical_study>
